timothy sykes logo
Record Growth in bioAffinity Technologies: CyPath Lung Shines Thumbnail
ADD US ONG Google News

Record Growth in bioAffinity Technologies: CyPath Lung Shines

JACK KELLOGG•UPDATED APR. 1, 2026, 9:19 AM ET
Reviewed by Tim Sykes Fact-checked by Ellis Hobbs

bioAffinity Technologies Inc. stocks have been trading up by 17.36 percent, fueled by FDA designations and promising results.

Candlestick Chart

Live Update At 09:18:40 EDT: On Wednesday, April 01, 2026 bioAffinity Technologies Inc. stock [NASDAQ: BIAF] is trending up by 17.36%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

In 2025, bioAffinity Technologies flexed its growth muscles with a massive jump in CyPath Lung diagnostic test sales. The noninvasive lung cancer test saw revenues climb by 87% while test volumes nearly doubled—showing a solid foothold in the market. However, this positive news was clouded by an overall revenue decrease, leading to a net loss of around $14.9 million, underlying its reliance on capital markets and a singular product line.

The company’s exit from unprofitable pathology services and securing $16.9 million in new funding is a significant move. But with all financial positives come challenges—chiefly the widening losses and a dependency on selling and successfully marketing the CyPath Lung test.

Examining the stock’s trading history shows a rollercoaster pattern not for the faint of heart, with price volatility reflecting investors’ cautious optimism. On Mar 31, 2026, BIAF closed at $3.83, showing an upward trajectory since mid-March when it was at $1.07. Key ratios, however, reveal a grim picture with high negative profit margins and low return on assets, indicating the depth of the financial liabilities facing bioAffinity. Their survival and growth hinge on strong market performance and a strategic pivot to thriving sectors.

Federal Support and Imminent Clinical Study

In a bid to revolutionize cancer diagnostics, bioAffinity has greenlit a robust 2,000-patient clinical study of its diagnostic tool, targeting those at high risk for non-invasive cancer diagnostics. The study levers federal investments at VA medical centers and large hospitals. Functioning as more than just market penetration, the initiative signals bioAffinity’s commitment to innovation and highlights its allure for government backing in cutting-edge healthcare solutions.

More Breaking News

The study’s potential to open further market avenues by establishing a benchmark in early lung cancer detection is promising. However, the outcome of this multi-site study is awaited with bated breath by stakeholders eager to assess the efficacy and future market acceptance of their promising technology.

Enhanced Applications Through Revolutionary Research

The bioAffinity team’s endeavors snagged attention at the AAAAI 2026 where they unveiled encouraging research spotlighting their technology’s potential—chiefly to predict responses to asthma and COPD drugs. Such advancements not only enhance the company’s reputation as a versatile innovator but may alter the medical data landscape by enabling doctors to customize treatments more precisely.

As bioAffinity widens its capabilities, the share prices are bound to reflect these research-findings’ potential impact on future revenues and shareholder confidence. However, the giant fiscal gaps documented in past financial reports might unsettle some die-hard investors eyeing a break-even.

Conclusion

bioAffinity Technologies paints a canvas of contrasts: exponential growth and future promise interspersed with financial strain and dependence on key markets. While their longstanding effort in the lung diagnostic sphere shows unwavering resilience and potential, maintaining its operating momentum remains a challenging task. As millionaire penny stock trader and teacher Tim Sykes says, “It’s better to go home at zero than to go home in the red.” This highlights the importance of cautious trading in navigating the company’s financial strain. Key future catalysts like federal collaborations and clinical trials could either unlock vast possibilities or magnify existing limitations, making the company’s journey an unpredictable yet riveting narrative.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading BIAF

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”